Glycophos (Sodium Glycerophosphate Pentahydrate)

Glycophos is indicated for clinical situations where phosphate replacement is required. It is commonly employed in the following contexts:

• Treatment of hypophosphatemia resulting from renal loss, malnutrition, or chronic alcoholism.
• Prevention of phosphate depletion in patients receiving total parenteral nutrition.
• Support of electrolyte balance during intensive care or major surgery.
• Adjunct therapy for metabolic disorders that involve phosphate deficiency.
• Management of phosphate loss associated with certain diuretic regimens.

Adverse reactions to Glycophos may vary in frequency and severity. Reported events include:

Common

• Mild injection site discomfort or erythema.
• Transient nausea or vomiting.
• Slight increase in serum sodium levels.
• Temporary elevation of serum calcium.
• Mild headache.
• Low-grade fever.

Serious

• Hyperphosphatemia leading to calcium‑phosphate precipitation.
• Severe hypernatremia causing neurological symptoms.
• Allergic reactions such as urticaria or anaphylaxis.
• Metabolic acidosis in susceptible individuals.
• Cardiac arrhythmias secondary to electrolyte imbalance.
• Acute kidney injury due to phosphate overload.

Before administering Glycophos, clinicians should consider several safety factors. Important precautions include:

• Assess baseline serum phosphate, calcium, and sodium levels to avoid over‑correction.
• Use caution in patients with renal insufficiency or on dialysis.
• Monitor for signs of fluid overload, especially in heart‑failure patients.
• Adjust dose in individuals with severe electrolyte disturbances.
• Avoid rapid infusion rates that may precipitate cardiovascular events.
• Consider pregnancy status; data on fetal safety are limited.
• Discontinue if an allergic reaction develops.

Glycophos may interact with other medications or therapies. Potential interactions are categorized as follows:

Avoid

• Concurrent use of high‑dose calcium supplements, which can increase the risk of calcium‑phosphate precipitation.
• Co‑administration with other phosphate‑containing intravenous solutions without monitoring.

Use with caution

• Loop diuretics that promote electrolyte loss, requiring closer monitoring of phosphate and sodium.
• ACE inhibitors or ARBs, which may affect renal handling of electrolytes.
• Antacids containing aluminum or magnesium, which can bind phosphate.
• Vitamin D analogues, as they influence calcium‑phosphate metabolism.
• Blood transfusions, which may alter phosphate balance.